Takeda Reaches Primary Endpoint in Phase III Gastric Cancer Trial

Key Facts

Takeda said the Phase III G-HOPE-001 trial of arcotatug tavatecan reached its primary endpoint of progression-free survival at the first interim analysis. The trial is testing the drug in patients with advanced gastric or gastroesophageal junction cancer who received prior treatment. The study includes China and Japan, according to the company’s announcement of the trial data. The announcement puts a positive result on the disease-progression measure at the center of the news, while the drug’s regulatory path remains tied to a review of the trial data. The published information did not provide overall survival rates or a numerical comparison between the treatment groups.

The announcement focuses on reaching the primary endpoint, progression-free survival, and does not include a published overall survival result. The available information therefore does not support saying the trial demonstrated an improvement in overall survival rates or assigning a numerical amount to any such improvement. The drug is intended for patients who received prior treatment, defining the population in which the trial result should be interpreted. Describing the result as reaching the endpoint does not, by itself, reveal the size of the effect or the difference between treatment and comparator. Assessment of those aspects remains tied to the evaluation of final results that Takeda cited in discussing a potential regulatory step.

Takeda said the trial data could provide a potential basis for a marketing authorization application in Japan, subject to an assessment of the final results. This means the company outlined a potential regulatory path, not a confirmed application date or an approval decision. In China, Innovent said an application for the drug had been submitted and accepted for priority review, according to the correction to the report. The regulatory paths are therefore moving in different forms: a conditional potential application in Japan and an application in China that has entered priority review. The available information did not specify when regulators in either country would make a decision.

The drug, which Takeda is developing under the code IBI343 and the name arcotatug tavatecan, is an experimental treatment targeting the CLDN18.2 protein. The company describes it as an antibody-drug conjugate carrying an exatecan payload. This description identifies the treatment’s nature and design, while the clinical trial result remains the basis for assessing it in the target patient population. Innovent had granted Takeda exclusive rights to develop, manufacture and commercialize the drug outside Greater China under the companies’ oncology partnership. The treatment has not yet received approval from the U.S. Food and Drug Administration or any other regulator, according to Takeda.

Takeda said it would present G-HOPE-001 data in a late-breaking session at the European Society for Medical Oncology Congress. The company scheduled the session for 23 October 2026, from 13:30 to 15:00 Central European Summer Time. The presentation follows the company’s announcement that the trial reached its primary endpoint, with assessment of final results remaining central to the potential Japanese regulatory step. In trading, Takeda’s New York-listed shares closed at $20.36 on 22 October 2026, according to EL7 data. The available information contains no further details on the stock’s movement during the session.